Stopping nucleot(s)ide analogues in non-cirrhotic HBeAg-negative chronic hepatitis B patients: HBsAg loss at 96 weeks is associated with low baseline HBsAg levels

SAL Hall; GS Burns; D Anagnostou; S Vogrin; V Sundararajan; D Ratnam; MT Levy; JS Lubel; A Nicoll; SI Strasser; W Sievert; PV Desmond; MC Ngu; P Angus; M Sinclair; C Meredith; G Matthews; PA Revill; K Jackson; M Littlejohn; D Bowden; SA Locarnini; K Visvanathan; A Thompson

Journal article

Stopping nucleot(s)ide analogues in non-cirrhotic HBeAg-negative chronic hepatitis B patients: HBsAg loss at 96 weeks is associated with low baseline HBsAg levels

SAL Hall, GS Burns, D Anagnostou, S Vogrin, V Sundararajan, D Ratnam, MT Levy, JS Lubel, A Nicoll, SI Strasser, W Sievert, PV Desmond, MC Ngu, P Angus, M Sinclair, C Meredith, G Matthews, PA Revill, K Jackson, M Littlejohn Show all

Alimentary Pharmacology and Therapeutics | Published : 2022

DOI: 10.1111/apt.16968

Download PDF

Abstract

Background and Aims: Current guidelines recommend long-term nucleot(s)ide analogue (NA) therapy for patients with HBeAg-negative chronic hepatitis B (CHB). However, disease remission has been described after stopping NA therapy, as well as HBsAg loss. Methods: We performed a prospective multi-centre cohort study of stopping NA therapy. Inclusion criteria were HBeAg-negative CHB, the absence of cirrhosis and HBVDNAView full abstract

University of Melbourne Researchers

Sara Vogrin Author

Vijaya Sundararajan Author

Paul Desmond Author

Peter Angus Author

Related Projects (1)

A STUDY OF TREATMENT DISCONTINUATION FOR CHRONIC HEPATITIS B PATIENTS

Guidelines currently recommend lifelong treatment for patients with chronic hepatitis B, with associated cost and risks of drug resistance a..

Grants

Awarded by Allos Therapeutics

Funding Acknowledgements

AJT received funding from the National Health and Medical Research Council of Australia (MRFF Practitioner Fellowship 1142976). Thiswork was supported by NHMRC Project Grant 1066536.